IRVING, Texas — Caris Life Sciences, a leading AI-driven TechBio company in the precision medicine space, has announced the successful close of a $168 million growth capital funding round, further strengthening its position as a trailblazer in molecular science and oncology diagnostics.
The new investment brings the company’s total capital raised since 2018 to an impressive $1.86 billion. The round was led by Braidwell LP, a prominent life sciences-focused investment firm, with participation from several high-profile new investors, including Perceptive Advisors, Woodline, and Ghisallo. Existing investors such as Millennium Management and First Light Asset Management also joined the round.
“This financing includes participation by some of the most knowledgeable healthcare investors with deep domain expertise and appreciation of the Caris platform and opportunity,” said Brian J. Brille, Vice Chairman and EVP of Caris Life Sciences. “We are proud to partner with our high-quality and diverse investor syndicate, which shares our mission to improve patient outcomes.”
The funding comes on the heels of several major advancements for the company. Most notably, Caris recently received FDA approval for MI Cancer Seek®, a groundbreaking diagnostic assay that combines Whole Exome and Whole Transcriptome Sequencing to profile solid tumors. It is the first test of its kind to receive FDA-approved companion diagnostic (CDx) indications for both adult and pediatric patients.
Additionally, Caris launched Caris Assure™ in 2024, a novel, non-invasive blood-based test that uses its proprietary circulating Nucleic Acid Sequencing (cNAS) technology. This approach allows for comprehensive molecular profiling by analyzing both cell-free DNA and RNA, along with DNA and messenger RNA from white blood cells, to identify and distinguish somatic tumors, clonal hematopoiesis, and germline variants.
The company’s leadership sees the new funding as a catalyst for expanding access to these cutting-edge technologies.
“Caris puts the patient at the center of everything we do,” said David D. Halbert, Caris’ Chairman, Founder and CEO. “This raise will help us bring our market-leading science and technologies to as many patients as possible and further our goal of revolutionizing precision medicine.”
Investors are betting on Caris’ ability to remain at the forefront of an increasingly competitive and dynamic precision medicine landscape.
“We are pleased to continue our relationship with Caris,” said Braidwell Partner Narendra Nayak. “We believe Caris is well-positioned as a precision medicine leader in this dynamic sector.”
As the global healthcare industry leans further into personalized approaches to cancer care, Caris Life Sciences’ momentum and investor confidence signal a strong trajectory for the company’s continued innovation and expansion.
